Zydus receives EIR for the API manufacturing facility at Dabhasa
Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as closed. Powered by Capital Market - Live News
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
a day ago
- Business Standard
Zydus Life receives USFDA EIR for Gujarat facility
Zydus Lifesciences has informed that it has received the establishment inspection report (EIR) from the U.S Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility located in Ankleshwar, Gujarat. The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the review, the inspection has been classified as no action indicated (NAI). The USFDA has concluded that the inspection is now closed. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.36% to Rs 975.20 on the BSE.
Business Standard
a day ago
- Business Standard
Stock Alert: Sterlite Tech, Zydus Life, Waaree Energies, Tanla Platform
Secutries in F&O Ban: Aditya Birla Fashion & Retail (ABFRL), Central Depository Services (CDSL), Chambal Fertilisers & Chemicals, Hindustan Copper, Indian Energy Exchange (IEX), Indian Renewable Energy Development Agency (IREDA), RBL Bank and Titagrah Rail Systems shares are banned from F&O trading on 11 June 2025. Stocks to Watch: Sterlite Technologies through its demerged business vertical, Global Services Business in consortium with Dilip Buildcon has entered into agreement with Bharat Sanchar Nigam. The agreement pertains to the design, supply, construction, installation, upgradation, operation, and maintenance of the middle-mile network under BharatNet for the Jammu & Kashmir and Ladakh Telecom Circles Package 13. The said contract is valued at Rs 2,631.14 crore. Zydus Lifesciences has received the establishment inspection report (EIR) report from the USFDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. The inspection has been classified as No Action Indicated (NAI). Waaree Energies has signed and executed the power purchase agreement (PPA) with Rewa Ultra Mega Solar (RUMSL) and M.P. Power Management Company (MPPMCL) for the supply of 150 MW Solar power to MPPMCL. Medplus Health Services subsidiary, Optival Health Solutions has received one suspension order for a drug license for store situated at Maharashtra. Tanla Platforms board is scheduled to meet on 16 June 2025, to consider the proposal for buyback of equity shares and other necessary matters. Kaynes Technology Indias board approved the further investment for an amount upto $ 1.03 million towards acquisition of equity shares upto 10,19,802 of Kaynes Holding, wholly owned subsidiary, at an issue price of $1.01 per share.
Business Standard
a day ago
- Business Standard
Zydus' Ankleshwar API unit clears USFDA inspection
Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the US FDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from 10th to 14th March 2025, and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is closed.
